| Macular retinal edema
Vabysmo vs Lucentis
Side-by-side clinical, coverage, and cost comparison for macular retinal edema.Deep comparison between: Vabysmo vs Lucentis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLucentis has a higher rate of injection site reactions vs Vabysmo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lucentis but not Vabysmo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vabysmo
Lucentis
At A Glance
Intravitreal injection
Every 4-8 weeks
VEGF-A and Ang-2 inhibitor
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Macular retinal edema
- Exudative age-related macular degeneration
- Macular retinal edema
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection every 4 weeks for first 4 doses, followed by dosing every 8, 12, or 16 weeks based on OCT and visual acuity evaluations; some patients may need every 4-week dosing.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 4 weeks for at least 4-6 doses, then interval adjusted to every 4-8 weeks based on CST and visual acuity evaluations.
Macular retinal edema 6 mg (0.05 mL) by intravitreal injection every 4 weeks.
Exudative age-related macular degeneration 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly; less frequent dosing with regular assessment may be considered after 3-4 initial monthly doses.
Macular retinal edema 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly.
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL of 6 mg/mL) intravitreal injection once monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly for up to 3 months; retreat as needed.
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to faricimab or any excipient in VABYSMO
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab or any excipient in LUCENTIS
Adverse Reactions
Most common (>=1%) Conjunctival hemorrhage, cataract, vitreous detachment, vitreous floaters, intraocular pressure increased, eye pain, intraocular inflammation, retinal pigment epithelial tear, eye irritation, lacrimation increased, ocular discomfort
Serious Endophthalmitis, retinal detachment, increase in intraocular pressure, thromboembolic events, retinal vasculitis and/or retinal vascular occlusion
Postmarketing Retinal vasculitis with or without retinal vascular occlusion
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, intraocular inflammation, cataract, foreign body sensation in eyes, eye irritation, lacrimation increased, nasopharyngitis, headache
Serious Endophthalmitis, retinal detachment, rhegmatogenous retinal detachment, iatrogenic traumatic cataract, thromboembolic events, fatal events in patients with DME and DR
Postmarketing Tear of retinal pigment epithelium in patients with neovascular AMD
Pharmacology
Faricimab is a humanized bispecific antibody that inhibits two pathways by binding to VEGF-A and Ang-2; VEGF-A inhibition suppresses endothelial cell proliferation, neovascularization, and vascular permeability, while Ang-2 inhibition promotes vascular stability and desensitizes blood vessels to the effects of VEGF-A.
Ranibizumab is a VEGF-A antagonist; a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vabysmo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Lucentis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (0/12)
UnitedHealthcare
Vabysmo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lucentis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vabysmo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lucentis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VabysmoView full Vabysmo profile
LucentisView full Lucentis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.